Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

$0.4 million increase in these unallocated research and development costs is spread out across personnel costs (increased headcount initiated last year, particularly with respect to non-clinical work in the celgosivir program), patent costs (advancement of MX-3253 patent applications) and other costs (higher level of activity in both the MX-3253 and MX-2401 programs).

We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis. We are currently focusing our resources on advancing the development of our non-partnered programs: celgosivir and MX-2401.

General and Corporate Expenses

General and corporate expenses in Q1/08 were $1.0 million (Q1/07: $0.8 million). Personnel costs were $0.5 million in Q1/08 (Q1/07: $0.5 million). The approximate $0.2 million increase in general and corporate costs in Q1/08 compared with Q1/07 is principally due to: (i) contract personnel in the Finance department engaged for internal controls, implementation of new accounting software and year end work; and (ii) greater legal and accounting costs.

Amortization

Amortization expense for equipment was approximately $0.1 million for Q1/08 (Q1/07: $0.1 million).

Amortization expense for intangible assets was approximately $0.1 million for Q1/08 (Q1/07: $0.2 million).

Other Income and Expenses

Interest income was $0.1 million for Q1/08 (Q1/07: $0.1 million).

Accretion expense related to the convertible royalty participation units for Q1/08 was $0.4 million (Q1/07: $0.3 million). This accretion expense is a non-cash expense resulting from accreting the liability component of the convertible royalty participation units to the maximum royalties payable of $29.5 million (will be reduced for actual royalties paid, any units converted into common shares and should the estimate of royalties payable decline below $29.5 million) over the estimated royalty payment te
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... developing therapeutics that address unmet medical needs in ... Elston will present at the Cantor Fitzgerald ... 8, 2015Time: , 4:45 PM EDTLocation: , Le ... archive): , www.juniperpharma.com, under  ,Investor, or  ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... Study will provide new insights on mechanics of fecal microbiota transplantation in C. ... to study the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... services to the federal government, announced in a paper published this week in ... a potential problem with the diagnostic techniques currently used to detect the Ebola ...
(Date:6/30/2015)... DENVER, CO (PRWEB) , ... June 30, 2015 , ... ... technologies, today announced that it has hired Gem Swartz to head up its account ... as senior account director. Both Gem and Amanda bring senior account management and delivery ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Matrix Marketing Group Expands Client Services Team 2
... http://www.obn.org.uk/obn_/menu.php?p=rss&rn=rssfeed&prechk_news=1 ... stories were recognised last night at the OBN ... network, which provides comprehensive support for biotech and ... the Awards at a capacity black tie event ...
... Sept. 13, 2011 Microban recently conducted ... and biofilm growth on High Consistency Rubber (HCR) ... of urinary catheters.  Urinary infections are a costly ... technologies have had limited success in reducing infection ...
... Portugal, Sept. 13, 2011 Metabolic Solutions Development Company, ... sensitizers, MSDC-0160 and MSDC-0602, stimulate progenitor cells ... instead of white fat cells. Brown fat, which diminishes ... The mechanism of action by which MSDC-0160 and MSDC-0602 ...
Cached Biology Technology:OBN's 2011 Annual Awards Dinner Celebrates UK Bioscience Success Stories 2OBN's 2011 Annual Awards Dinner Celebrates UK Bioscience Success Stories 3Microban Medical Silver Antimicrobial Technologies for HCR Silicone Achieve 5 Log Reductions in Bacteria Growth and Prevent Biofilm Formation 2Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes 2
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und ... QGEN ; Frankfurt Prime Standard: QIA) hat heute in ... Produktlinie Investigator ® für ... Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine ...
(Date:6/17/2015)... Fla. , June 17, 2015  Crossmatch™, ... today announced that its U.are.U ® 4500 ... Togo,s Eateries, Inc., a ... sandwich chain, to increase security, improve accountability and ... readers enable instant, non-repudiable identity confirmation for employee ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... the coast of El Salvador late last year directly ... to test results released today by the Wildlife Conservation ... from the Salvadoran government and the US Agency for ... White journeyed to the southern coast of El Salvador ...
... cancer followed by radiation therapy often experience breast ... surgery. Researchers at the McGowan Institute for Regenerative ... University, have developed a polymer-based therapy for breast ... filler after surgery and a clinically effective therapy. ...
... the 21st century, state-of-the-art anti-aging technologies may extend human ... host of social and economic challenges, says biologist Shripad ... these medical advances would have major implications for the ... and Virginia Morrison Professor of Population Studies, will give ...
Cached Biology News:Red Tide causes sea turtle die-off in El Salvador 2Chemotherapy gel may fight breast cancer and reduce breast deformity 2World faces challenge as life expectancies lengthen, scientist says 2World faces challenge as life expectancies lengthen, scientist says 3World faces challenge as life expectancies lengthen, scientist says 4
... Application: The simple three step procedure (PCR, ... be completed in one day. The typical ... than 80%. , Features and Benefits: , ... cloned into any expression vector , High ...
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... be used with all 96-well ... stacking of covered plates ... with automated systems ... are available for use with ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,667-7) ... assistance. ID clarifier: barcoded, bulk ...
Biology Products: